Cargando…

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Tumor protein 53 (TP53) mutation predicts an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL), but the molecular basis for this association remains unclear. In several malignancies, the cytidine deaminase apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) has been rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuzhao, Wu, Zhaoxing, Hao, Yuanyuan, Yu, Teng, Li, Xian, Liang, Yun, Li, Jinfan, Huang, Liansheng, Xu, Yang, Li, Xiuzhen, Xu, Xiaohua, Wang, Weiqin, Xu, Genbo, Zhang, Xiaohong, Lv, Qinghua, Fang, Yongming, Xu, Rongzhen, Qian, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112561/ https://www.ncbi.nlm.nih.gov/pubmed/35592333 http://dx.doi.org/10.3389/fimmu.2022.888250

Ejemplares similares

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report
por: Zhang, Xuzhao, et al.
Publicado: (2021)

Identification of the novel Np17 oncogene in human leukemia
por: Wu, Bowen, et al.
Publicado: (2020)

Associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population
por: He, Xiuting, et al.
Publicado: (2019)

Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase
por: Roelofs, Pieter A., et al.
Publicado: (2023)

A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors
por: Xu, Ying, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B
por: Chen, Yanmeng, et al.
Publicado: (2020)

DNA cytosine and methylcytosine deamination by APOBEC3B: enhancing methylcytosine deamination by engineering APOBEC3B
por: Fu, Yang, et al.
Publicado: (2015)

Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report
por: Zhang, Xuzhao, et al.
Publicado: (2020)

Distinct Determinants in HIV-1 Vif and Human APOBEC3 Proteins Are Required for the Suppression of Diverse Host Anti-Viral Proteins
por: Zhang, Wenyan, et al.
Publicado: (2008)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
por: Zhou, Lanlan, et al.
Publicado: (2022)

Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression
por: Warren, Cody J., et al.
Publicado: (2017)

Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer
por: Xia, Siyu, et al.
Publicado: (2021)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
por: Lu, Tingxun, et al.
Publicado: (2023)

APOBEC3B: Future direction of liver cancer research
por: Yang, Xingyue, et al.
Publicado: (2022)

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
por: Xu, Hao, et al.
Publicado: (2023)

GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3
por: Gara, Sudheer Kumar, et al.
Publicado: (2020)

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression
por: Yamazaki, Hiroyuki, et al.
Publicado: (2020)

APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells
por: Bogerd, Hal P., et al.
Publicado: (2006)

Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B
por: Shi, K., et al.
Publicado: (2016)

The Role of APOBECs in Viral Replication
por: Xu, Wendy Kaichun, et al.
Publicado: (2020)

The Roles of APOBEC3G Complexes in the Incorporation of APOBEC3G into HIV-1
por: Ma, Jing, et al.
Publicado: (2013)

BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B
por: Coelho, Matthew A., et al.
Publicado: (2018)

Activation of CaMKIIγ potentiates T-cell acute lymphoblastic leukemia leukemogenesis via phosphorylating FOXO3a
por: Jiang, Xudong, et al.
Publicado: (2017)

Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer
por: Nik-Zainal, Serena, et al.
Publicado: (2014)

Involvement of APOBEC3B in mutation induction by irradiation
por: Saito, Yohei, et al.
Publicado: (2020)

Genetic inhibitors of APOBEC3B-induced mutagenesis
por: Mertz, Tony M., et al.
Publicado: (2023)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

APOBEC3A suppresses cervical cancer via apoptosis
por: Li, Zishuai, et al.
Publicado: (2023)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia
por: Wu, Zhaoxing, et al.
Publicado: (2019)

CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis
por: Yang, Linlin, et al.
Publicado: (2020)

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report
por: Chen, Liting, et al.
Publicado: (2022)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature
por: Zhao, Aiqi, et al.
Publicado: (2023)

Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma
por: Shen, Qiu-Dan, et al.
Publicado: (2021)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6im73448urdi32hnq793rv3hla